Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1725 participants.

Also called NCT02680574

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,725 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02680574
  • EudraCT 2015-004774-14
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Malaysia, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02680574. Randomized; no masking; primary purpose treatment. Start 2016-02 (actual); primary completion 2020-06-18 (actual). Results posted on 2022-06-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Condition
Anemia
Condition
Non-Dialysis-Dependent Chronic Kidney Disease
Intervention (Drug)
Vadadustat
Intervention (Drug)
Darbepoetin alfa
Lead sponsor
Akebia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02680574
Content hash
573c8b141c26236f4c09371d7789924cf48e538258a2f3cf51ed21f084f449dc